Form 4: Abbott Laboratories Director Acquires Stock Equivalent Units

Director Robert J. Alpern acquired 75 stock equivalent units of Abbott Laboratories on June 30, 2024, through director fees credited to a grantor trust.

Summary

• Robert J. Alpern, a director of Abbott Laboratories, acquired 75 stock equivalent units on June 30, 2024.
• These units were obtained through director fees credited to a stock equivalent unit account under a grantor trust.
• The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
• The price of the stock equivalent units was $103.91.
• Following the transaction, Alpern beneficially owns 9,754 stock equivalent units.
• These units are payable in cash generally at age 65 or upon retirement from the board.
• The balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects a director increasing their stake in the company, which is generally viewed favorably, but it's a routine transaction.

Positives

• The acquisition of stock equivalent units demonstrates the director's continued investment in the company's future.
• The dividend reinvestment feature further increases the director's stake in Abbott Laboratories.

Future Outlook

The stock equivalent units are payable in cash generally at age 65 or upon retirement from the board, indicating a long-term investment perspective.

Industry Context

Directors often receive compensation in the form of stock or stock equivalent units to align their interests with those of shareholders. This Form 4 filing reflects a standard practice of directors receiving equity-based compensation.

Stakeholder Impact

• The transaction signals to shareholders that the director has a vested interest in the company's performance.

Key Dates